FACT SHEET

Humira

DRUG INFORMATION

- **FDA Approval:** 11 total indications. Major disease indications include rheumatoid arthritis (2003), psoriatic arthritis (2005), and Crohn’s disease (2007)
- **Company:** AbbVie
- **Drug Type:** Biologic
- **On the U.S. Market since:** 2002
- **Generic/Biosimilar approved by FDA:** 2016 (Not on the market)

PRICING

- **Annual List Price:** $44,000¹
- **Price Trend:** 100% increase from 2012 to 2018²
- **Annual Medicare Spending:** $5,339,052,157³
- **Increase in Average Spend per Medicare Beneficiary (2014-2018):** 94%
- **Annual Medicaid Spending:** $1,642,701,843
- **Medicare Spending Rank:** 5⁴

PATENT LANDSCAPE

- **First Patent Filed:** 1994
- **Total Patent Applications:** 257
- **Patents Issued:** 130
- **Filed After FDA Approval:** 90%
- **Duration of Patent Protection:** 39.0 years (Nov 1994 - Nov 2033)

DELAYED COMPETITION IN THE U.S.

- Humira biosimilars launched in Europe in Oct 2018. Within 6 months, prices dropped by 70%.
- In the U.S., AbbVie negotiated deals with 8 drugmakers to delay the launch of biosimilars until 2023.
- Between 2018 and 2023, an estimated $77 billion will be spent on Humira in the U.S.

DID YOU KNOW?  

AbbVie has been granted just 6 patents for Humira in Europe. Lower-cost biosimilar versions of the drug have been available in that region since 2018. By contrast, AbbVie’s 130 granted U.S. patents will prohibit biosimilars from entering the market until 2023.

³ 2018, most recent year available for all Medicare and Medicaid data  / ⁴ assumes total combined spending for HumiraPen (#7) and Humira (#6)